Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

7.22
-0.3200-4.24%
Post-market: 7.230.0100+0.14%19:15 EDT
Volume:1.20M
Turnover:8.70M
Market Cap:596.17M
PE:-2.10
High:7.53
Open:7.48
Low:7.15
Close:7.54
52wk High:13.24
52wk Low:2.68
Shares:82.57M
Float Shares:49.97M
Volume Ratio:0.67
T/O Rate:2.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4360
EPS(LYR):-3.0696
ROE:-90.88%
ROA:-43.24%
PB:2.83
PE(LYR):-2.35

Loading ...

MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street -- WSJ

Dow Jones
·
Mar 03

Replimune Group Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 05

Replimune Group Is Maintained at Outperform by Wedbush

Dow Jones
·
Feb 04

Wedbush Raises Price Target on Replimune Group to $19 From $18, Keeps Outperform Rating

MT Newswires Live
·
Feb 04

Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Feb 04

Replimune Group Q3 EPS $(0.77) Beats $(0.78) Estimate

Benzinga
·
Feb 03

Replimune Amends Loan Agreement With Hercules Capital to Access Up to $155 Million

Reuters
·
Feb 03

Replimune meldet für die neun Monate bis Dezember 2025 einen Anstieg der Ausgaben für Forschung und Entwicklung auf 168,86 Mio. USD, plus 25 Prozent

Reuters
·
Feb 03

Replimune reports Q3 net loss of USD 70.93 million

Reuters
·
Feb 03

BRIEF-Replimune Group Q3 Net Income USD -70.93 Million

Reuters
·
Feb 03

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Feb 03

Replimune Group Q3 Cash & Investments USD 269.1 Million

THOMSON REUTERS
·
Feb 03

Replimune Group Q3 Basic EPS USD -0.77

THOMSON REUTERS
·
Feb 03

Replimune Group Showcases Oncolytic Immunotherapy Advancements for Melanoma in New Presentation

Reuters
·
Jan 15

Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness

Simply Wall St.
·
Dec 17, 2025

Replimune Group Director Kapil Dhingra Reports Sale of Common Shares

Reuters
·
Dec 12, 2025

Replimune CEO Sushil Patel Reports Disposal of Common Shares

Reuters
·
Dec 05, 2025

Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A

LiveWire
·
Nov 21, 2025

Replimune Group Q2 Net Income USD -83.1 Million

Reuters
·
Nov 20, 2025

Replimune Group Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025